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ABSTRACT
Introduction Up to 50% of patients develop post- 
thrombotic syndrome (PTS) after an above knee deep 
vein thrombosis (DVT). The aim of the study was to 
determine the effect of graduated compression stockings 
in preventing PTS after DVT.
Methods and analysis Pragmatic, UK multicentre 
randomised trial in adults with first above knee DVT. The 
standard of care arm is anticoagulation. The intervention 
arm will receive anticoagulation plus stockings (European 
class II, 23–32 mm Hg compression) worn for a median 
of 18 months. The primary endpoint is PTS using the 
Villalta score. Analysis of this will be through a time to 
event approach and cumulative incidence at median 6, 
12 and 18 months. An ongoing process evaluation will 
examine factors contributing to adherence to stockings to 
understand if and how the behavioural interventions were 
effective.
Ethics and dissemination UK research ethics committee 
approval (reference 19/LO/1585). Dissemination though 
the charity Thrombosis UK, the Imperial College London 
website, peer- reviewed publications and international 
conferences.
Trial registration number ISRCTN registration number 
73041168.
INTRODUCTION
Deep vein thrombosis (DVT) occurs in 1–2 
per 1000 adults in the UK1 and half will 
go on to develop lifelong disability from 
post- thrombotic syndrome (PTS).2 PTS is 
defined as ‘chronic venous symptoms or 
signs secondary to deep vein thrombosis’3 for 
example, leg pain, oedema and skin changes, 
progressing in 5% to ulceration. The average 
age of patients developing PTS is 55 years, 
meaning that most are of working age.4 
Individuals with PTS have difficulty walking 
and therefore maintaining employment, 
and have a level of disability comparable to 
chronic obstructive pulmonary disease.5 The 
pathophysiology of PTS is sustained venous 
hypertension from venous outflow obstruc-
tion and valvular incompetence.6
The recent negative results of the 
ATTRACT trial have refocussed attention on 
the effectiveness of graduated compression 
stockings (GCS) in preventing PTS.7 The UK 
National Institute for Health and Care Excel-
lence (NICE) and the American College of 
Chest Physicians recently withdrew their 
recommendations for the use of GCS in the 
prevention of PTS based on the results of the 
SOX trial.8 9 However, European guidelines 
still recommend stockings.10 11
A recent systematic review examined 
randomised controlled trials (RCTs) in this 
area.12 Three RCTs inclusive of 1177 patients 
examined the use of GCS providing 30–40 mm 
Hg compression at the ankle versus either no 
stocking,13 14 or a placebo.4 Follow- up ranged 
from 2 to 5 years with a primary outcome 
measure of cumulative incidence of PTS. 
There was important clinical, methodolog-
ical and statistical heterogeneity between 
trials (I2=94%). Key clinical differences were 
variable inclusion of patients with chronic 
venous disease, variable baseline rates of PTS 
and differing anatomy of DVT. Key method-
ological differences were the use of a placebo 
stocking versus a no stocking control arm, 
Strengths and limitations of this study
 ► Pragmatic multicentre randomised trial that will in-
form international practice.
 ► Stockings are a low cost, widely applicable, safe in-
tervention across high and low resource healthcare 
systems.
 ► Assessor blind design.
 ► Examines behavioural factors affecting adherence.
 ► No placebo stocking arm due to ease of breaking 
blinding.
 on A









pen: first published as 10.1136/bm















pen: first published as 10.1136/bm















pen: first published as 10.1136/bm















pen: first published as 10.1136/bm















pen: first published as 10.1136/bm















pen: first published as 10.1136/bm















pen: first published as 10.1136/bm















pen: first published as 10.1136/bm















pen: first published as 10.1136/bm















pen: first published as 10.1136/bm















pen: first published as 10.1136/bm















pen: first published as 10.1136/bm















pen: first published as 10.1136/bm















pen: first published as 10.1136/bm





2 Thapar A, et al. BMJ Open 2021;11:e044285. doi:10.1136/bmjopen-2020-044285
Open access 
and differing PTS scoring systems.15 Additionally, adher-
ence varied between 56% and 93%.
The largest placebo- controlled trial showed no differ-
ence in the outcome of PTS with the use of stockings. 
The other two assessor blind trials showed absolute risk 
reductions of 23% and 39% with the use of stockings. 
There appeared to be more benefit from the use of GCS 
in populations with a higher baseline risk of PTS.12
Compression hosiery to avoid post- thrombotic 
syndrome (CHAPS) is a multicentre, pragmatic, assessor 
blind, RCT of adults with a first above knee DVT, 
comparing the regular use of a stocking with no stocking 
in preventing PTS.
PTS comprises a substantial economic burden on 
health systems, patients and society due to days lost to 
illness. The cost of three pairs of high- quality GCS per 
year is around £150, but this expense may be offset to 
some extent by lower costs elsewhere. Under standard 
care, around 50% of DVTs result in PTS.15 Given the high 
cost of treatment of PTS, especially venous ulcers and the 
impact on quality of life,16 the addition of GCS could be a 
cost- effective addition to standard treatment.
METHODS AND ANALYSIS
CHAPS is a multicentre, pragmatic, assessor- blind superi-
ority RCT. The trial will follow patients up for a median of 18 
months (range 6–30 months). The study commenced on 1 
May 2019 and is due to close on 31 January 2023. Please see 
figure 1 for a Consolidated Standards of Reporting Trials 
diagram and online supplemental appendix 1 for a Stan-
dard Protocol Items: Recommendations for Interventional 
Trials checklist.
Eligibility
Table 1 details inclusion and exclusion criteria. Peripheral 
arterial disease will be screened for using pedal pulse palpa-
tion, with ankle brachial pressure index where equivocal.
Recruitment
Recruitment will be from emergency departments, ambu-
latory care, DVT, vascular, obstetric or haematology clinics 
in 11 UK hospitals (see www. ISCTRN. com for details), 
via the National Institute for Health Research (NIHR) 
Clinical Research Network and trial nurses. Recruitment 
of 864 participants is planned over 24 months from both 
academic and non- academic centres. Informed consent will 
be obtained in writing (online supplemental appendix 2) 
by the local study nurse.
Study arms
Standard care
Anticoagulation for a minimum of 3 months (as per NICE 
recommendations8). The type and duration of anticoagu-
lation beyond 3 months will be determined by local guide-
lines with the expectation that this will be a direct oral 
anticoagulant for the majority. A placebo stocking arm was 
not included because of ease of breaking blinding. GCS are 
not be recommended for treatment of acute leg pain.17
Intervention arm
Anticoagulation plus a standardised below knee compres-
sion stocking (European class II, 23–32 mm Hg compres-
sion) worn during waking hours until the end of the trial, 
or until an alternative is required, for example, compres-
sion bandaging for venous ulceration. Minor variations 
such as change in fabric, open or closed toe or thigh length 
stockings are permissible if they aid adherence.
A number of behavioural aids will be made available to 
patients in the stocking arm:
 ► Patient education video at baseline
 ► Patient and carer refresher session for stocking 
donning and doffing within 2 weeks
 ► Free provision of a donning aid if required
 ► Cotton stocking for summer use
The following participant retention strategies have been 
employed:18
 ► Travel cost reimbursement
 ► Weekly text message reminders to wear stockings
 ► A Facebook support group for stocking wearers
 ► Next of kin contact for follow- up
Stockings will be fitted and issued by a local research 
nurse at first visit. Within 2 weeks, there will be a face- to- face 
or video call refresher session for donning and doffing with 
the research nurse, patient and carer.
Randomisation
Participants will undergo 1:1 web- based randomisation by 
a local research nurse via the Research Electronic Data 
Capture (REDCap) database hosted at the Edinburgh Clin-
ical Trials Unit.
Primary effectiveness endpoint
The primary outcome measure is PTS as assessed by the 
recommended Villalta score at a median of 18 months 




2. Employment status (change in number of days work-
ing from baseline)
3. Quality of life measured using VEINES (Venous Insuf-
ficiency Epidemiological and Economic Study)- QoL 
and EuroQoL EQ5D scales
4. Adherence to stockings and anticoagulants
5. Cost- effectiveness of stocking prescription
Sample size
The sample size calculation for CHAPS was based on the 
cumulative incidence of PTS at 18 months in the recent 
SOX trial.4 A minimum clinically important difference of 
a 10% absolute risk reduction in PTS with GCS was chosen 
multifactorially, based on patient consultation, the degree 
of behaviour change required by patients and to be less 
than that found in earlier positive stocking trials (absolute 
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Figure 1 CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials; NICE, National Institute for Health and 
Care Excellence. B- IPQ, Brief illness perception questionnaire; BSQ, Beliefs about stockings questionnaire; MARS, Medicine 
adherence rating scale; NICE CG 144, National Institute for Health and Clinical Excellence Clinical Guideline 144; Qol, Quality of 
life; TIQ, Treatment Intrusiveness Questionnaire; VEINS, Venous insufficiency epidemiological and economic study.
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risk reduction 23%–39%),13 14 reflecting improvements in 
anticoagulation. With 864 participants randomised 1:1, 
the study will have 90% power at a 5% level of significance 
using a test of binomial proportions to detect an absolute 
reduction in the incidence of PTS from 30% in the stan-
dard care arm to 20% in the intervention arm, allowing 
for 10% loss to follow- up. This reduction would represent 
a number needed to treat of 10 to prevent one case of 
PTS.
Internal pilot study
An internal pilot study will follow a randomly selected 
group of 200 patients over the first 12 months, leading to 
a mixed- methods process evaluation of factors contributing 
to GCS adherence.
Adaptations of the Medication Adherence Rating Scale 
(MARS),20 Brief Illness Perception Questionnaire (B- IPQ),21 
22 Treatment Intrusiveness Questionnaire (TIQ)23 and a 
novel Beliefs about Stockings Questionnaire (BSQ) will be 
given to participants at the 1 month, 6 and 12 months and 
final follow- up assessments. Qualitative interviews from a 
purposive sample of 20 patients at 1 month and 7 months 
will be used to examine factors affecting GCS adherence in 
further depth.
Trial stopping criteria
A combination of self- reported adherence and stocking 
reordering behaviour will be used to adjudicate adher-
ence at the end of the pilot. The criteria for adequate 
1 year adherence is ≥70% of participants in the interven-
tion arm wearing the stocking for ≥4 days per week, with a 
documented stocking reorder in the last 6 months. This is 
the remit of the Trial Steering Committee (TSC). If this is 
achieved, the trial will continue into the main study. If this 
is not achieved, the trial will terminate and a process eval-
uation of factors influencing adherence will be reported.
Assessment of outcomes and of blinding
The study is assessor blind. An independent researcher at 
each site will perform Villalta assessments blind to treat-
ment allocation. Participants will remove their stockings 
on the night prior to their clinic visit and be instructed 
not to discuss stockings during their assessment. The 
following questionnaires will be administered at follow- up 
visits: EQ5D, VEINES- QoL and MARS. Employment status 
(average number of days per week currently working) and 
healthcare resource use (contacts and outcomes of interac-
tions with health services) will also be collected. Data will 
be entered by the local research team onto the web- based 
database REDCap.
Blinding will be evaluated by asking assessors which arm 
they believe the participant is in. Unblinding is permis-
sible only if a stocking- related significant adverse event is 
suspected.
Data monitoring
In line with NIHR recommendations, a Trial Steering 
Committee (TSC) and an independent Data Monitoring 
Committee have been appointed to oversee trial conduct 
(please see online supplemental appendix 3). A Trial 
Manager together with the TSC will oversee trial progress. 
The study will be monitored by the Edinburgh Clinical 
Trials Unit to assess the progress of the study, verify adher-
ence to the protocol and Good Clinical Practice guidelines 
and to review the completeness, accuracy and consistency 
of the data, through the use of independent data monitors. 
Pseudoanonymised data will be stored on REDCap, with a 
local key held by site Principal Investigators (PIs) to link this 
to clinical patient records. Data will be filed for 10 years as 
per local policy and then deleted.
Data analysis
The primary analysis will be an intention- to- treat analysis 
that does not adjust for adherence to stockings. This will 
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
Symptomatic presentation of first deep 
vein thrombosis, <2 weeks from diagnosis
Previously intolerant of or already wearing graduated compression stockings for more than 
1 month
Imaging confirmed, lower limb deep vein 
thrombosis (popliteal, femoral, iliac or 
combination)
Contraindication to wearing graduated compression stockings or allergy to fabric
Ability to give informed consent Life expectancy <2 years
Age 18 years or over Ankle brachial pressure index <0.8 (measured when pedal pulses equivocal)
  Bilateral deep vein thrombosis
Previous chronic venous insufficiency (patients with existing chronic skin changes or ulceration, 
defined as C4,5,6 by CEAP classification)
Pre- existing post- thrombotic syndrome, significant leg pain (eg, knee arthritis, spinal claudication) 
or oedema (eg, lymphoedema)
Newly diagnosed cancer, metastatic cancer or cancer undergoing active treatment or palliation
Contraindication to anticoagulation
CEAP, Clinical, Etiological, Anatomical, Pathophysiological classification.
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be performed independently by the Edinburgh Clinical 
Trials Unit who will have sole access to the final REDCap 
data set. This will determine the treatment effect given the 
adherence in the trial, which is appropriate to gauge real- 
world effectiveness. The occurrence of PTS will be analysed 
in both a time- to- PTS approach (since it is possible that the 
treatment effect may both avert PTS, and also possibly delay 
its onset) and through analysis of cumulative incidence at 
a median of 6, 12 and 18 months (as recommended by the 
International Society for Thrombosis and Haemostasis and 
peer reviewers).3 Prespecified subgroup analyses including 
iliac vein involvement and body mass index >30 kg/m2. 
To determine the effect of optimum adherence (wearing 
a stocking for the trial duration for ≥4 days per week) on 
outcome, a secondary analysis will use Complier Average 
Causal Estimation modelling through instrumental variable 
regression. The results of the process evaluation will report 
which behavioural components change participants knowl-
edge, beliefs and intentions regarding stocking usage. 
Participants who discontinue the study will have informa-
tion until date of leaving available for analysis.
Health economic analysis
Resource arising from the trial interventions, visits and 
admissions to hospital, general practice visits, community 
nursing and social and personal care will be collected 
during follow ups at 6 months, 12 months and the final visit 
and supplemented by case note review.
Employment status (average number of days worked per 
week, along with days lost from work and normal activities) 
will be collected from patients by questionnaire at baseline 
and at 6 months, 12 months and final follow- up.
A within- trial analysis and a decision model will be 
constructed. In both cases, the main analyses will be 
performed from the perspective of the UK NHS and 
Personal Social Services at 2018/2019 prices. Secondary 
analyses will be performed from a societal perspective. The 
results of the analyses will be presented as estimates of mean 
incremental costs, effects, and, incremental cost per quality- 
adjusted life year. Sensitivity analyses will be conducted to 
test the robustness of the results to alternative assumptions 
about model structure, assumptions and input data. Prob-
abilistic sensitivity analysis will be conducted using Monte- 
Carlo simulation.
Ethics and dissemination
The trial was granted ethical approval (National Research 
Ethics Service ref. 19/LO/1585).
Protocol amendments will be circulated by email to inves-
tigators and study nurses to cascade to participants. Dissem-
ination of results will be by the CHAPS coinvestigators in 
peer- reviewed journals and international conferences and 
to a lay audience through the Thrombosis UK website.
Adverse events and liability
All treatment- related adverse events will be collected by site 
PIs. The chief investigator (CI) will be notified of all serious 
adverse events within 24 hours. All serious adverse events 
will be reported to the research ethics committee and 
sponsor, if, in the opinion of the CI, the event was related 
to the intervention. All related adverse events and serious 
adverse events will be recorded and summarised by treat-
ment strategy. The sponsor (Imperial College London) 
holds a relevant insurance.
Patient and public involvement
Patients, their carers’ and relatives were involved in a three- 
stage consultation process during the trial development 
stage, incorporating NIHR INVOLVE methodology. This 
consisted of a series of semistructured interviews, a survey 
run via Thrombosis UK, and review of the CHAPS research 
plan and lay summary. Responses and feedback were 
incorporated into the design and budget of CHAPS. The 
Imperial Vascular PPI group has contributed four patients 
and two members of the public will advise the steering 
committee for the duration of the trial.
CONCLUSION
The NIHR funded CHAPS trial will examine whether class 
II GCS prevent PTS, are cost- effective and the factors influ-
encing adherence at a median 18 months follow- up (range 
6–30 months).
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Title 1 1 Descriptive title identifying the study design, population, interventions, 
and, if applicable, trial acronym 
Trial registration 1 2a Trial identifier and registry name. If not yet registered, name of 
intended registry 
 2b All items from the World Health Organization Trial Registration Data 
Set 
Protocol version 3 3 Date and version identifier 
Funding 3 4 Sources and types of financial, material, and other support 
Roles and 
responsibilities 
4 5a Names, affiliations, and roles of protocol contributors 
3 5b Name and contact information for the trial sponsor 
 3 5c Role of study sponsor and funders, if any, in study design; collection, 
management, analysis, and interpretation of data; writing of the report; 
and the decision to submit the report for publication, including whether 
they will have ultimate authority over any of these activities 
 App2 5d Composition, roles, and responsibilities of the coordinating centre, 
steering committee, endpoint adjudication committee, data 
management team, and other individuals or groups overseeing the 
trial, if applicable (see Item 21a for data monitoring committee) 
Introduction    
Background and 
rationale 
7 6a Description of research question and justification for undertaking the 
trial, including summary of relevant studies (published and 
unpublished) examining benefits and harms for each intervention 
 9 6b Explanation for choice of comparators 
Objectives 10 7 Specific objectives or hypotheses 
Trial design 9 8 Description of trial design including type of trial (eg, parallel group, 
crossover, factorial, single group), allocation ratio, and framework (eg, 
superiority, equivalence, noninferiority, exploratory) 
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 Methods: Participants, interventions, and outcomes 
Study setting 9 9 Description of study settings (eg, community clinic, academic hospital) 
and list of countries where data will be collected. Reference to where 
list of study sites can be obtained 
Eligibility criteria 9 10 Inclusion and exclusion criteria for participants. If applicable, eligibility 
criteria for study centres and individuals who will perform the 
interventions (eg, surgeons, psychotherapists) 
Interventions 9 11a Interventions for each group with sufficient detail to allow replication, 
including how and when they will be administered 
9 11b Criteria for discontinuing or modifying allocated interventions for a 
given trial participant (eg, drug dose change in response to harms, 
participant request, or improving/worsening disease) 
9 11c Strategies to improve adherence to intervention protocols, and any 
procedures for monitoring adherence (eg, drug tablet return, 
laboratory tests) 
9 11d Relevant concomitant care and interventions that are permitted or 
prohibited during the trial 
Outcomes 10 12 Primary, secondary, and other outcomes, including the specific 
measurement variable (eg, systolic blood pressure), analysis metric 
(eg, change from baseline, final value, time to event), method of 
aggregation (eg, median, proportion), and time point for each 
outcome. Explanation of the clinical relevance of chosen efficacy and 
harm outcomes is strongly recommended 
Participant 
timeline 
15 13 Time schedule of enrolment, interventions (including any run-ins and 
washouts), assessments, and visits for participants. A schematic 
diagram is highly recommended (see Figure) 
Sample size 10 14 Estimated number of participants needed to achieve study objectives 
and how it was determined, including clinical and statistical 
assumptions supporting any sample size calculations 
Recruitment 9 15 Strategies for achieving adequate participant enrolment to reach 
target sample size 
 Methods: Assignment of interventions (for controlled trials) 
Allocation:    
Sequence 
generation 
10 16a Method of generating the allocation sequence (eg, computer-
generated random numbers), and list of any factors for stratification. 
To reduce predictability of a random sequence, details of any planned 
restriction (eg, blocking) should be provided in a separate document 
that is unavailable to those who enrol participants or assign 
interventions 
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10 16b Mechanism of implementing the allocation sequence (eg, central 
telephone; sequentially numbered, opaque, sealed envelopes), 
describing any steps to conceal the sequence until interventions are 
assigned 
Implementation 10 16c Who will generate the allocation sequence, who will enrol participants, 
and who will assign participants to interventions 
Blinding 
(masking) 
11 17a Who will be blinded after assignment to interventions (eg, trial 
participants, care providers, outcome assessors, data analysts), and 
how 
 11 17b If blinded, circumstances under which unblinding is permissible, and 
procedure for revealing a participant’s allocated intervention during 
the trial 
 Methods: Data collection, management, and analysis 
Data collection 
methods 
10,11 18a Plans for assessment and collection of outcome, baseline, and other 
trial data, including any related processes to promote data quality (eg, 
duplicate measurements, training of assessors) and a description of 
study instruments (eg, questionnaires, laboratory tests) along with 
their reliability and validity, if known. Reference to where data 
collection forms can be found, if not in the protocol 
 12 18b Plans to promote participant retention and complete follow-up, 
including list of any outcome data to be collected for participants who 
discontinue or deviate from intervention protocols 
Data 
management 
12 19 Plans for data entry, coding, security, and storage, including any 
related processes to promote data quality (eg, double data entry; 
range checks for data values). Reference to where details of data 
management procedures can be found, if not in the protocol 
Statistical 
methods 
12 20a Statistical methods for analysing primary and secondary outcomes. 
Reference to where other details of the statistical analysis plan can be 
found, if not in the protocol 
 12 20b Methods for any additional analyses (eg, subgroup and adjusted 
analyses) 
 12 20c Definition of analysis population relating to protocol non-adherence 
(eg, as randomised analysis), and any statistical methods to handle 
missing data (eg, multiple imputation) 
 Methods: Monitoring 
Data monitoring App2 21a Composition of data monitoring committee (DMC); summary of its role 
and reporting structure; statement of whether it is independent from 
the sponsor and competing interests; and reference to where further 
details about its charter can be found, if not in the protocol. 
Alternatively, an explanation of why a DMC is not needed 
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 11 21b Description of any interim analyses and stopping guidelines, including 
who will have access to these interim results and make the final 
decision to terminate the trial 
Harms 12 22 Plans for collecting, assessing, reporting, and managing solicited and 
spontaneously reported adverse events and other unintended effects 
of trial interventions or trial conduct 
Auditing 12 23 Frequency and procedures for auditing trial conduct, if any, and 
whether the process will be independent from investigators and the 
sponsor 
 Ethics and dissemination 
Research ethics 
approval 




13 25 Plans for communicating important protocol modifications (eg, 
changes to eligibility criteria, outcomes, analyses) to relevant parties 
(eg, investigators, REC/IRBs, trial participants, trial registries, journals, 
regulators) 
Consent or assent 9 26a Who will obtain informed consent or assent from potential trial 
participants or authorised surrogates, and how (see Item 32) 
 9 26b Additional consent provisions for collection and use of participant data 
and biological specimens in ancillary studies, if applicable 
Confidentiality 12 27 How personal information about potential and enrolled participants will 
be collected, shared, and maintained in order to protect confidentiality 
before, during, and after the trial 
Declaration of 
interests 
3 28 Financial and other competing interests for principal investigators for 
the overall trial and each study site 
Access to data 12 29 Statement of who will have access to the final trial dataset, and 




13 30 Provisions, if any, for ancillary and post-trial care, and for 
compensation to those who suffer harm from trial participation 
Dissemination 
policy 
13 31a Plans for investigators and sponsor to communicate trial results to 
participants, healthcare professionals, the public, and other relevant 
groups (eg, via publication, reporting in results databases, or other 
data sharing arrangements), including any publication restrictions 
 13 31b Authorship eligibility guidelines and any intended use of professional 
writers 
 12 31c Plans, if any, for granting public access to the full protocol, participant-
level dataset, and statistical code 
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Appendices    
Informed consent 
materials 
App1 32 Model consent form and other related documentation given to 
participants and authorised surrogates 
Biological 
specimens 
n.a 33 Plans for collection, laboratory evaluation, and storage of biological 
specimens for genetic or molecular analysis in the current trial and for 
future use in ancillary studies, if applicable 
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 
Explanation & Elaboration for important clarification on the items. Amendments to the 
protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT 
Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” 
license. 
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CHAPS Trial Commitees 
Trial Steering Committee 
Bold = independent member 
Dr Peter MacCallum 
Senior Lecturer in 
Haematology 
Chair 
Dr Susie Shapiro Consultant Haematologist Member 
Mr Isaac Nyameke Consultant Vascular Surgeon Member 
Dr Stephen Gerry 
Senior medical statistician and 
NIHR doctoral research fellow  
Member 
Professor Alun Davies Professor of Vascular Surgery Member 
Mr Andrew Steptowe PPI member Public Observer 
Mr David Brae PPI member Public Observer 
Mr  Ankur Thapar Co-applicant   Observer 
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Data monitoring committee 
Bold = independent member 
 
 
Mr Richard Bulbulia Consultant Vascular Surgeon Chair 
Dr Natalie Staplin 
Senior Statistician – Renal 
Studies Group 
Member 
Mr Richard Haynes Associate Professor Member 
Mr Keith Poskitt 
Consultant Vascular and 
General Surgeon 
Member 
Mr Imad Adamestam Trial Statistician  
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Delete this line, then print on Hospital/Trust headed paper 
Site ID:  Initials:  
Participant Trial ID: Principal Investigator Name: 
  
Compression Hosiery to Avoid Post-thrombotic Syndrome (CHAPS) 
IRAS 263041 
                                           PATIENT CONSENT FORM                                Please initial box  
1. I confirm that I have read and understand the information sheet dated 25/06/2020 
(Version 3.0) for the above study and have had the opportunity to ask questions 
which have been answered fully. 
2. I understand that my participation is voluntary and that I am free to leave the study 
at any time without my medical care or legal rights being affected. 
3. I understand that relevant sections of my medical records may be looked at by 
authorised individuals from the research team, from regulatory bodies, from the 
study Sponsor, or from the NHS Trust in order to check that the study is being 
carried out correctly. I give permission, provided that strict confidentiality is 
maintained, for these bodies to have access to my medical records for the above 
study. 
4. I understand that my mobile phone number and email address will be stored until 
the end of the study securely by the University of Edinburgh and used to send 
weekly text message reminders to you until your participation on the study ends 
5. I understand that my pseudonymised data will be transferred to the University Of 
Granada for the analysis. 
6.  I agree to my data being entered onto a secure database held at the University of 
Edinburgh, in accordance with the Data Protection Act 2018. 
7. I agree to my GP, or any other doctor treating me, being notified of my participation 
in this study. I agree to my GP being involved in the study, including any necessary 
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8. If during the study my clinical care team determine that I have lost capacity to 
provide informed consent, I will be withdrawn from the study and any identifiable 
data collected with consent would be retained and used in the study. 
9. I agree to take part in the CHAPS study. 
Optional consent section (please initial the appropriate box) 
10. I give/do not give consent for information collected about me to be used to        
support other research in the future, including those outside of the EEA.     
 
     Give consent                           Do not give consent   
11. I give/do not give consent for my data may be linked with appropriate national 
databases, including Hospital Episode Statistics (HES), and the National Vascular 
Database as well as for longer term follow-up in the event the trial is extended 
     Give consent                           Do not give consent   
12. I give/do not give consent to be contacted in the future with regards to this study, 
should the study be extended. 
      Give consent                           Do not give consent   
 
 
Full Name of Participant  Date  Signature 
 
 
Name of Person Taking 
Consent 
 Date  Signature 
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